Holen Sie sich die Stockscreener-App
1.08
2.26%
-0.025
Schlusskurs vom Vortag:
$1.105
Offen:
$1.1
24-Stunden-Volumen:
45,839
Relative Volume:
0.02
Marktkapitalisierung:
$4.84M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-3.60M
KGV:
-0.9076
EPS:
-1.19
Netto-Cashflow:
$-3.37M
1W Leistung:
-13.60%
1M Leistung:
-13.25%
6M Leistung:
+1.89%
1J Leistung:
-45.23%
1-Tages-Spanne:
$1.01
$1.10
1-Wochen-Bereich:
$1.01
$1.2333
52-Wochen-Spanne:
$0.77
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Vergleichen Sie SILO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.95 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.16 | 337.66M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.265 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.25 | 139.95M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
10.50 | 137.23M | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Increases By 38.7% - Defense World
Silo Pharma Inc. (SILO) reports earnings - Quartz
Silo Pharma, Inc. SEC 10-K Report - TradingView
SILO Stock Price and Chart — NASDAQ:SILO - TradingView
Silo Pharma begins key study for PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Doses First Participant In IND-Enabling GLP Study Of SPC-15 For PTSD Treatment - Nasdaq
Silo Pharma begins key study for PTSD treatment - Investing.com
Silo Pharma Achieves Key Milestone With First Dosing In IND-Enabling GLP Study For SPC-15 As A Groundbreaking PTSD Treatment - Marketscreener.com
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - The Manila Times
Silo Pharma Achieves Key Milestone with First Dosing in - GlobeNewswire
Major PTSD Treatment Advance: FDA Fast-Track Path Opens for Revolutionary Drug SPC-15 - Stock Titan
Silo Pharma Unveils Strategic Initiatives and Drug Pipeline - TipRanks
Silo Pharma secures patent for stress disorder prophylactic - Investing.com
Silo Pharma secures patent for stress disorder prophylactic By Investing.com - Investing.com UK
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - Marketscreener.com
MarketsMedicine Hat News - Financial Content
Silo Pharma Granted US Patent for Intranasal Post-Traumatic Stress Disorder Treatment - Marketscreener.com
Silo Pharma, Inc. Receives Issuance Notification for Patent Related to SPC-15 Treatment for PTSD - Nasdaq
Silo Files Provisional Patent For SPC-15 Combination Treatment To Target Stress-Induced Disorders - Nasdaq
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - The Manila Times
Silo Pharma Expands Intellectual Property Portfolio with - GlobeNewswire
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for ... - The Bakersfield Californian
Revolutionary Mental Health Treatment Patent: Silo Pharma's Dual-Action SPC-15 Shows Promising Results - StockTitan
Silo Pharma reports positive early data on pain treatment implant By Investing.com - Investing.com Nigeria
Silo Pharma Announces Positive Initial Pharmacokinetic, - GlobeNewswire
Silo Pharma reports positive early data on pain treatment implant - Investing.com
SILO’s valuation metrics: A comprehensive analysis - US Post News
Silo Pharma's SP-26 Shows Promising Initial Safety And Absorption Data For Pain Relief - Nasdaq
Silo Pharma Reports Positive Safety Update from SP-26 Ketamine Implant Study with No Serious Side Effects Observed - Nasdaq
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 - The Bakersfield Californian
Revolutionary Pain Treatment: SILO's Ketamine Implant Aces Initial Safety Tests - StockTitan
Monitoring SILO Pharma Inc (SILO) after recent insider movements - Knox Daily
SILO Pharma Inc (SILO) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
SILO Pharma Inc’s Market Journey: Closing Strong at 1.79, Up 11.18 - The Dwinnex
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewswire
Silo Pharma files provisional patent for PTSD treatment - MSN
Silo Pharma Files Breakthrough PTSD Treatment Patent, Expands Columbia Tech Portfolio - StockTitan
Looking For A Good Stock? Let This SILO Pharma Inc (NASDAQ: SILO) Analysis Help. - Stocks Register
After A Patent Win, Analysts Think This Penny Stock Can Gain 465% In 2025 - Barchart
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Silo Pharma awarded U.S. patent for PTSD treatment - Yahoo Finance
Silo Pharma secures patent for PTSD intranasal treatment By Investing.com - Investing.com Nigeria
SILO Pharma flies high on impending patent for intranasal PTSD drug - Mugglehead
Crude Oil Down 1%; US Weekly Jobless Claims Decline - Benzinga
Silo Pharma shares soar on patent allowance news By Investing.com - Investing.com South Africa
Silo Pharma shares soar on patent allowance news - Investing.com India
Silo Pharma secures patent for PTSD intranasal treatment - Investing.com
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial - The Manila Times
Silo Pharma Secures Key Patent Protection for PTSD Treatment SPC-15, Strengthens IP Portfolio - StockTitan
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):